Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierIQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Business segments
Q2 2026 · $2.04BThe company’s own SEC segment disclosure.
- Research And Development Solutions$1.14B56%
- Commercial Solutions$895.0M44%
IQVIA (IQV) reported revenue of $4.15B in Q1 2026 (quarter ended March 31, 2026), up 8.4% from the same quarter a year earlier. That came with a gross margin of 33% and net income of $274M (6.6% of revenue). For the full year FY2025, revenue was $16.3B (+5.9% year on year) and net income $1.36B. Its largest segment in 2026-Q2 was Research And Development Solutions at $1.14B, 56% of the disclosed total, just ahead of Commercial Solutions at 44%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #11 of 29 by Smart Score